Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 in advanced high-grade sarcoma
NCT05262101Phase 2Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bemosesuglimab in Sarcoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoint: Overall response rate up to 48 weeks. Started May 2022; status: terminated.
02
Drugs
bemosesuglimab
03
Conditions
Sarcoma
Beyond the preview
Go deeper on NCT05262101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262101.